Announcements Trials
Browse Landscape

Phase

Phase 1/2 2Phase 2 1Phase 1 1

Status

Terminated 2Completed 2

Sponsor Class

INDUSTRY 4

Study Type

Interventional 4

Sponsor

Cancer Type

Dermatologic 4Gastrointestinal 3Sarcoma 1

Conditions

Melanoma 4Sarcoma 1Neoplasm Metastasis 1

Interventions

pembrolizumab 181Nivolumab 117Ipilimumab 97Dacarbazine 48trametinib 37dabrafenib 353-ingenyl angelate 35Vemurafenib 33cemiplimab 27atezolizumab 24Temozolomide 24binimetinib 23Paclitaxel 22Imiquimod 22encorafenib 17avelumab 17Carboplatin 17Aminolevulinic Acid 17spartalizumab 16cobimetinib 16Cyclophosphamide 15Cisplatin 15Fluorouracil 14talimogene laherparepvec 13HhAntag691 11Gels 11Drug Therapy 11Bevacizumab 11lenvatinib 10durvalumab 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × IMM-101 × Dermatologic × Clear all
NCT03009058 2024-11-25

MODULATE

Immodulon Therapeutics Ltd

Phase 1/2 Terminated
2 enrolled 7 charts
DermatologicSarcoma

Melanoma, Neoplasm Metastasis, Sarcoma

NCT03711188 2024-04-29

A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma

Immodulon Therapeutics Ltd

Phase 2 Completed
16 enrolled 14 charts
Dermatologic

Melanoma

NCT01559818 2023-06-22

A Long Term Follow up Study for Patients Who Previously Took Part in the Phase I Study IMM-101-001

Immodulon Therapeutics Ltd

Phase 1/2 Terminated
10 enrolled 12 charts
Dermatologic

Melanoma

NCT01308762 2012-12-06

A Clinical Study, to Evaluate the Safety and Tolerability of Intradermal IMM-101 in Adult Melanoma Cancer Patients

Immodulon Therapeutics Ltd

Phase 1 Completed
19 enrolled 10 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡